Research with Purpose 2024 | 26-28 November | Tangalooma Island, Queensland
NFMRI is pleased to be holding its sixth conference Research with Purpose 2024 at Tangalooma Island (Qld) from the 26-28th November 2024. This unique event is built around Q&A panel sessions that engage highly with participants and led by content experts. The event focuses on building a culture, support and funding ecosystem where industry, government, academia, venture capital and philanthropy intersect to better support biomedical innovations from beginning to end.
Over the course of three days, delegates can expect to be part of a highly engaging and thought provoking event. With strict no-solicitation policies and Chatham House Rules, the discussions will be robust and candid. The event is intentionally modest in size, bringing together experts and key decision makers from relevant sectors to help share information between delegates and speakers. The conference has a strong focus of building cross-sector networks and developing robust, professional relationships to better enable collaborations.
Our conference at Tangalooma Island Resort will facilitate networking with thought leaders and decision makers creating new relationships, connections and concepts to assist with informed decisions and contributions in the development of new initiatives and policies to support Australia’s biomedical research ecosystem for years to come.
We are honoured to have Emeritus Professor Ian Chubb AC – preeminent neuroscientist and academic who was the Chief Scientist of Australia from 2011-2016 – open the conference, set the scene and lead the discussion.
In addition, Professor Andrew Wilks will be delivering the inaugural Peter Bowen Oration on the 26th of November 2024. Professor Wilks is an accomplished academic who has completed a rare ‘trifecta’: discovering and patenting a number of important drug discovery targets (JAK1 and JAK2), founding one of Australia’s most successful biotech companies (Cytopia) and co-inventing and leading the team that delivered the JAK inhibitor, Momelotinib. Professor Wilks is Executive Chairman at SYNthesis med them, CEO at SYNthesis Research and CEO at Catalyst Tx.
We invite you to join us and be part of the discussion that helps ignite change and lead to impact. Early bird registrations are now open and for a limited time, we are offering grant making charities and students two for one registrations.